Jupiter Asset Management Ltd. Trims Stake in Elanco Animal Health Incorporated $ELAN

Key Points

• Jupiter Asset Management trimmed its Elanco Animal Health stake by 2.2% in the fourth quarter, selling 83,055 shares but still holding 3.63 million shares valued at about $82.2 million.
• Elanco reported stronger-than-expected quarterly results, with EPS of $0.40 versus $0.34 expected and revenue of $1.37 billion, up 14.9% year over year.
• Insider buying and analyst sentiment were both positive: the CEO and another executive bought shares in May, and analysts currently rate the stock Moderate Buy with an average target price of $28.20.

Jupiter Asset Management Ltd. reduced its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,633,794 shares of the company's stock after selling 83,055 shares during the period. Jupiter Asset Management Ltd. owned 0.73% of Elanco Animal Health worth $82,233,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Huntington National Bank grew its holdings in shares of Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company's stock worth $38,000 after acquiring an additional 1,087 shares during the period. Torren Management LLC purchased a new position in shares of Elanco Animal Health in the 4th quarter valued at approximately $46,000. Fifth Third Bancorp lifted its stake in shares of Elanco Animal Health by 3,018.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company's stock valued at $58,000 after purchasing an additional 2,807 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Elanco Animal Health by 43.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company's stock valued at $70,000 after purchasing an additional 938 shares during the period. Finally, Nkcfo LLC purchased a new position in shares of Elanco Animal Health in the 3rd quarter valued at approximately $75,000. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $23.94 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The firm has a market cap of $11.96 billion, a price-to-earnings ratio of -47.88, a price-to-earnings-growth ratio of 2.55 and a beta of 1.69. The business has a 50-day simple moving average of $22.98 and a two-hundred day simple moving average of $23.32. Elanco Animal Health Incorporated has a fifty-two week low of $13.09 and a fifty-two week high of $27.72.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same period last year, the business posted $0.37 EPS. The company's revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Rajeev A. Modi bought 4,911 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the purchase, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the company's stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 1.14% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on ELAN shares. Citigroup raised their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, May 7th. UBS Group reiterated a "buy" rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Leerink Partners boosted their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 24th. JPMorgan Chase & Co. upped their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, May 7th. Finally, KeyCorp raised their target price on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $28.20.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.